Effectiveness and Safety of Intensive Triplet Chemotherapy Plus Bevacizumab, FIr-B/FOx, in Young-Elderly Metastatic Colorectal Cancer Patients

Table 2

Activity, efficacy, and effectiveness of FIr-B/FOx regimen in young-elderly patients according to KRAS genotype.

	All		KRAS wild-type		KRAS mutant
	Intent-to-treat analysis		Intent-to-treat analysis		Intent-to-treat analysis
	No.	%	No.	%	No.	%
Enrolled pts	28	100	13	100	13	100
Evaluable pts	28	100	13	100	13	100
Objective response	22	79 (CI ± 15)	12	92 (CI ± 15)	10	77 (CI ± 24)
Partial response	19	68	10	77	9	69
Complete response	3	11	2	15	1	8
Stable disease	1	4	—	—	1	8
Progressive disease	5	18	1	8	2	15
Median PFS, months	11		14		7
Range	3–78+		4–78+		3–69+
Progression events	23	82	10	77	11	85
Median OS, months	21		38		19
Range	6–78+		8–78+		6–69+
Deaths	19	68	9	69	8	61.5
Liver metastasectomies	5		3		2
No/overall pts	5/28	18	3/13	23	2/13	15
No/Pts with liver metastases	5/17	29	3/7	43	2/8	25
No/Pts with L-L metastases	3/8	37.5	2/4	50	1/3	33
Pathologic complete responses	2	40	—	—	2	100

pts: patients; PFS: progression-free survival; OS: overall survival; L-L: liver-limited.